April 2024 – Page 10

MedinCell and AbbVie Collaborate on Long-Acting Injectable Development with a Potential Value of $1.9 Billion

1 year ago talkbio0Tagged AbbVie, development aspects, Long-acting injectable, Medincell, Papillary thyroid carcinoma

MedinCell, AbbVie, Long-acting injectable, Development pact, $1.9 billion

Director/Vice President of Translational Research: Leading the Bridge from Discovery to Clinical Development

1 year ago talkbio0Tagged approvals, Biological Assay, Biological Markers, Biomarker Strategy, Clinical Development, Clinical Trial Design, Cross-Functional Collaboration, development aspects, Discover, Drug Molecule Development, End Point, Leadership, PK/ PD/, Preclinical Development, regulatory, Target, Team Building, Translational Research, Biomedical, Translational Science Leadership

Translational Research, Biomarker Discovery, Preclinical Development, Early Clinical Development, Drug Molecule Development, Translational Science Leadership, Biomarker Development, Target Engagement Strategies, Assay Development (PK/ PD/ Immunogenicity), Clinical Trial Design, Endpoint and Biomarker Strategy, Team Building and Leadership, Cross-Functional Collaboration, Regulatory Approvals

Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis

1 year ago talkbio0Tagged Clinical, Lesion, Magnetic Resonance Imaging, Multiple Sclerosis, Multiple Sclerosis, Ocrevus, Relapse, Roche (company)

Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures

Detailed PHOENIX Study Reveals Relyvrio’s Failure in ALS Treatment

1 year ago talkbio0Tagged Amylyx, Amyotrophic Lateral Sclerosis, Clinical Research, Clinical Trials, Failure (biologic function), Phoenix Pharmaceuticals, Relyvrio

Relyvrio, PHOENIX study, Amyotrophic Lateral Sclerosis (ALS), Trial failure, Amylyx Pharmaceuticals

Eli Lilly’s Zepbound Shows Promising Results in Reducing Sleep Apnea Severity in Pivotal Trials

1 year ago talkbio0Tagged Continuous Positive Airway Pressure, Eli, Eli Lilly, Glucagon-Like Peptide-1 Receptor, Obesity, Sleep Apnea, Obstructive, tirzepatide, trials, Weight Loss, Zepbound

Eli Lilly, Zepbound, Sleep Apnea, Obstructive Sleep Apnea (OSA), Pivotal Trials, Obesity, GLP-1 Receptor Agonist, Tirzepatide, CPAP, Weight Loss

Sanofi Downsizes IGM Antibody Deal, Reduces Oncology Focus

1 year ago talkbio0Tagged Antibodies, Biosciences, Immunoglobulin M, Neoplasms, Partnership, sanofi

Sanofi, IGM Biosciences, antibody deal, oncology, downsizing, partnership

Sage Therapeutics’ Dalzanemdor Outcomes Amid Parkinson’s Miss

1 year ago1 year ago talkbio0Tagged dalzanemdor

Sage Therapeutics Dalzanemdor Parkinson

Canaan Secures Additional $100M for Biopharma Fund and Welcomes Pfizer Veteran to Team

1 year ago talkbio0Tagged Biopharma Fund, Canaan, Investments, Pfizer Veteran

Canaan, Biopharma Fund, $100M Investment, Pfizer Veteran

AbbVie Secures Deal with Medincell for Long-Acting Injectable Platform, Valued up to $1.9 Billion

1 year ago talkbio0Tagged AbbVie, Biotechnology, long-acting injectable platform, Medincell

AbbVie, Medincell, Long-acting injectable platform, Biotechnology, Deal, $1.9 billion

CMS to Increase Reimbursement for New Sickle Cell Gene Therapies through Outcomes-Based Agreements

1 year ago talkbio0Tagged Administrative action, Burden, Casgevy, Cells, Centers for Medicaid and Medicare (CMS) Pnl, Central, CGT, Equitable Access, Fertility, Grail, Increased, Lyfgenia, Medicaid Access, Medicare & Medicaid Services, OBAs, Outcomes-Based Agreements, Reimbursement, sickle cell gene therapies

CMS (Centers for Medicare & Medicaid Services), Sickle Cell Gene Therapies, Increased Reimbursement, Outcomes-Based Agreements (OBAs), Cell and Gene Therapy (CGT) Access Model, Medicaid Access, Casgevy, Lyfgenia, Fertility Preservation Services, Equitable Access, Administrative Burden Reduction